Prospective, longitudinal comparison of neurocognitive change in pediatric brain tumor patients treated with proton radiotherapy versus surgery only.
Adolescent
Brain Neoplasms
/ pathology
Child
Child, Preschool
Cognition Disorders
/ etiology
Craniospinal Irradiation
/ adverse effects
Female
Follow-Up Studies
Humans
Intelligence
/ radiation effects
Longitudinal Studies
Male
Memory, Short-Term
/ radiation effects
Neurosurgical Procedures
/ adverse effects
Prognosis
Prospective Studies
Proton Therapy
/ adverse effects
IQ
cognitive
pediatric brain tumor
processing speed
proton radiotherapy
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
10 06 2019
10 06 2019
Historique:
pubmed:
13
2
2019
medline:
2
7
2020
entrez:
13
2
2019
Statut:
ppublish
Résumé
Proton radiotherapy (PRT) reduces the volume of normal tissue receiving radiation dose, which may lead to better neurocognitive outcomes. We examined change in neurocognitive scores over time in pediatric brain tumor patients treated with proton craniospinal irradiation (CSI), proton focal RT, or surgery only. Patients received annual neurocognitive evaluations for up to 6 years. We examined Full Scale IQ (FSIQ), Verbal Comprehension Index (VCI), Perceptual Reasoning Index (PRI), Working Memory Index (WMI), and Processing Speed Index (PSI) scores. General linear mixed models examined change in scores over time by treatment group, adjusting for significant covariates. Scores from 93 patients treated between 2012 and 2017 (22 proton CSI, 31 proton focal, and 40 surgery only) were examined. Treatment groups were similar on gender (51.6% male), age at treatment (median = 9.7 y), and length of follow-up (median = 2.9 y). The surgery only group had proportionately more gliomas (P < 0.001), and the proton CSI group had more infratentorial tumors (P = 0.001) and higher total RT dose (P = 0.004). The proton focal and surgery only groups exhibited stable neurocognitive scores over time across all indexes (all P > 0.05). In the proton CSI group, WMI, PSI, and FSIQ scores declined significantly (P = 0.036, 0.004, and 0.017, respectively), while VCI and PRI scores were stable (all P > 0.05). Focal PRT was associated with stable neurocognitive functioning into survivorship. Outcomes were similar whether patients received focal PRT or no radiotherapy, even in neurocognitive domains known to be particularly radiosensitive. Proton CSI emerged as a neurocognitive risk factor, consistent with photon outcomes research.
Sections du résumé
BACKGROUND
Proton radiotherapy (PRT) reduces the volume of normal tissue receiving radiation dose, which may lead to better neurocognitive outcomes. We examined change in neurocognitive scores over time in pediatric brain tumor patients treated with proton craniospinal irradiation (CSI), proton focal RT, or surgery only.
METHODS
Patients received annual neurocognitive evaluations for up to 6 years. We examined Full Scale IQ (FSIQ), Verbal Comprehension Index (VCI), Perceptual Reasoning Index (PRI), Working Memory Index (WMI), and Processing Speed Index (PSI) scores. General linear mixed models examined change in scores over time by treatment group, adjusting for significant covariates.
RESULTS
Scores from 93 patients treated between 2012 and 2017 (22 proton CSI, 31 proton focal, and 40 surgery only) were examined. Treatment groups were similar on gender (51.6% male), age at treatment (median = 9.7 y), and length of follow-up (median = 2.9 y). The surgery only group had proportionately more gliomas (P < 0.001), and the proton CSI group had more infratentorial tumors (P = 0.001) and higher total RT dose (P = 0.004). The proton focal and surgery only groups exhibited stable neurocognitive scores over time across all indexes (all P > 0.05). In the proton CSI group, WMI, PSI, and FSIQ scores declined significantly (P = 0.036, 0.004, and 0.017, respectively), while VCI and PRI scores were stable (all P > 0.05).
CONCLUSIONS
Focal PRT was associated with stable neurocognitive functioning into survivorship. Outcomes were similar whether patients received focal PRT or no radiotherapy, even in neurocognitive domains known to be particularly radiosensitive. Proton CSI emerged as a neurocognitive risk factor, consistent with photon outcomes research.
Identifiants
pubmed: 30753584
pii: 5308916
doi: 10.1093/neuonc/noz041
pmc: PMC6558072
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
809-818Subventions
Organisme : NCI NIH HHS
ID : K07 CA157923
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA187202
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Clin Oncol. 2005 Aug 20;23(24):5511-9
pubmed: 16110011
Cancer. 2011 Dec 1;117(23):5402-11
pubmed: 21563173
J Clin Oncol. 2001 Aug 1;19(15):3470-6
pubmed: 11481352
J Clin Oncol. 2013 Oct 1;31(28):3494-500
pubmed: 23980078
J Neurosurg Pediatr. 2010 Apr;5(4):329-34
pubmed: 20367335
Lancet Oncol. 2004 Jul;5(7):399-408
pubmed: 15231246
Radiother Oncol. 2017 Jul;124(1):89-97
pubmed: 28655455
J Child Neurol. 2009 Nov;24(11):1387-96
pubmed: 19841427
Pediatr Radiol. 2009 Feb;39 Suppl 1:S65-70
pubmed: 19083214
Nat Clin Pract Oncol. 2004 Dec;1(2):97-103; quiz 1 p following 111
pubmed: 16264827
Childs Nerv Syst. 2010 Sep;26(9):1173-88
pubmed: 20552208
Pediatr Blood Cancer. 2005 May;44(5):487-93
pubmed: 15586355
Psychooncology. 2013 Sep;22(9):1979-86
pubmed: 23447439
Psychooncology. 2008 Nov;17(11):1157-61
pubmed: 18636431
J Clin Exp Neuropsychol. 2016 Dec;38(10):1065-76
pubmed: 27295192
Lancet Oncol. 2016 Mar;17(3):287-298
pubmed: 26830377
J Clin Oncol. 2008 Oct 10;26(29):4765-70
pubmed: 18779602
Neuropsychology. 2008 Mar;22(2):159-68
pubmed: 18331158
Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):400-7
pubmed: 26254679
J Clin Oncol. 2009 Aug 1;27(22):3691-7
pubmed: 19581535
Neuro Oncol. 2017 Nov 29;19(12):1673-1682
pubmed: 29016818
Pediatr Blood Cancer. 2018 Sep;65(9):e27245
pubmed: 29856521
Pediatr Blood Cancer. 2013 Aug;60(8):1350-7
pubmed: 23444345
J Clin Oncol. 2001 Apr 15;19(8):2302-8
pubmed: 11304784
J Clin Oncol. 2014 Jun 10;32(17):1760-8
pubmed: 24516024
Neuropsychology. 2003 Oct;17(4):548-55
pubmed: 14599268
Pediatr Blood Cancer. 2009 Sep;53(3):417-23
pubmed: 19479971
J Clin Oncol. 2016 Apr 1;34(10):1043-9
pubmed: 26811522
Neuropsychology. 2000 Apr;14(2):189-200
pubmed: 10791859
J Neurosurg. 2006 Dec;105(6 Suppl):444-51
pubmed: 17184075